150,697 Shares in Immuneering Corporation $IMRX Purchased by 683 Capital Management LLC

683 Capital Management LLC acquired a new position in Immuneering Corporation (NASDAQ:IMRX) in the 4th quarter, HoldingsChannel reports. The fund acquired 150,697 shares of the company’s stock, valued at approximately $992,000.

Several other large investors also recently added to or reduced their stakes in the company. Empery Asset Management LP purchased a new stake in Immuneering in the 4th quarter worth about $17,601,000. Vanguard Group Inc. increased its holdings in Immuneering by 128.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after acquiring an additional 1,358,322 shares during the last quarter. State Street Corp increased its holdings in Immuneering by 1,289.7% in the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after acquiring an additional 2,229,374 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Immuneering by 10.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock worth $13,121,000 after purchasing an additional 195,176 shares during the period. Finally, Citadel Advisors LLC bought a new position in Immuneering in the 3rd quarter worth about $6,602,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on IMRX shares. Oppenheimer restated an “outperform” rating on shares of Immuneering in a research note on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. Chardan Capital restated a “buy” rating and issued a $20.00 target price on shares of Immuneering in a research note on Tuesday, May 19th. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research note on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Immuneering presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Price Performance

NASDAQ:IMRX opened at $4.41 on Thursday. The business has a 50 day moving average of $5.09 and a 200 day moving average of $5.34. The company has a market capitalization of $285.33 million, a price-to-earnings ratio of -3.77 and a beta of 0.38. Immuneering Corporation has a 1-year low of $2.06 and a 1-year high of $10.08.

Immuneering (NASDAQ:IMRX) last released its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.09. As a group, sell-side analysts anticipate that Immuneering Corporation will post -1.12 EPS for the current year.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.